Dr Reddy’s Share Price in Focus; Partners with Takeda to Distribute QDENGA in India

Dr Reddy’s entered into the agreement with Takeda Biopharmaceuticals India Private Limited on September 18, 2026. Under the deal, Dr Reddy’s will handle the promotion, distribution and marketing of QDENGA in the private market for both children and adults in India.   

Takeda will continue to handle the public market in India. It will also be responsible for manufacturing and importing the vaccine.  

Dr Reddy’s Gets Private Market Rights 

Dr Reddy’s will have exclusive rights to distribute and market QDENGA in India's private market. The agreement covers vaccination for both pediatric and adult patients.  

There is no upfront payment or milestone payment under the agreement. The companies have not disclosed the other commercial terms.  

The deal is not an acquisition. Takeda is also not a related party of Dr Reddy’s, and the filing states that the promoter group and group companies have no interest in Takeda.  

QDENGA Expected to Launch in 2027 

QDENGA received marketing approval from India's Central Drugs Standard Control Organization (CDSCO) in July 2026 for people aged 4 to 60 years. It is the first dengue vaccine approved by CDSCO in India.  

QDENGA is designed to protect against all four dengue virus serotypes. It is given in two doses, with the second dose administered three months after the first.  

Also Check: Pharmaceuticals Stocks

Takeda to Continue Public Market Role 

The agreement only covers India's private market. Takeda will retain its rights in the public market and will continue to own QDENGA's legal and brand rights in India.  

Dr Reddy’s will work with Takeda on disease awareness, engagement with healthcare professionals, promotion and distribution of the vaccine in the private market.  

Takeda's vaccine has been approved in 43 countries since 2022, and more than 32 million doses have been distributed globally through public and private programmes, according to the companies.  

Read More: IndiGo Share Price Gains as It Hikes Ancillary Charges for Infant Travel, Baggage and Priority Services! 

Dr Reddy's Laboratories Share Price Performance  

As of 18 September 2026, Dr Reddy Laboratories share price closed at ₹1,185.30 per share, reflecting a surge of 0.88% from the previous trading session. 

Conclusion  

Dr Reddy’s Laboratories has entered into an exclusive agreement with Takeda to promote and distribute QDENGA in India's private market. Takeda will continue to handle manufacturing, imports and the public market. QDENGA is expected to be available in India in the first half of 2027, subject to the required processes.   

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Turn insights into action - Open Free Demat Account with Angel One and start investing instantly.